Karen White's wrongful-termination lawsuit against Purdue

Karen White’s wrongful-termination lawsuit against Purdue Pharma became an early test of whether the company’s OxyContin sales practices could be challenged in court through the experience of one of its own former sales representatives. White claimed that Purdue had fired her for refusing to sell to doctors who were illegally overprescribing the drug; the jury ruled for the company. The case gave grieving families a possible route toward accountability, then exposed how difficult it was to turn their suspicions about a powerful corporation into a legally provable claim.

White’s Claim and the Families’ Hopes

White, a former Purdue sales representative in Florida, was fired in 2002. The company attributed her dismissal to paperwork irregularities, poor communication skills, and declining sales. White’s legal filing offered a different account: she maintained that she had been fired because she refused to sell to doctors who were illegally overprescribing OxyContin. The dispute therefore placed two questions beside each other: why White lost her job, and whether the company’s sales practices had crossed a legal boundary.

For Relatives Against Purdue Pharma (RAPP), the case had significance beyond one employee’s dismissal. The group’s parents hoped that White’s claim would show that Purdue’s marketing practices had crossed a line the courts could recognize. Their hopes were sharpened by the frustration of trying to persuade regulators to respond to addiction and loss. Barbara Van Rooyan had argued that OxyContin should not be used for chronic, noncancer pain before other treatments had been explored, while still believing it had a place in terminal and acute pain care. RAPP’s campaign sought both justice and greater public awareness of the drug’s risks.

The case also unfolded against evidence that complicated Purdue’s public position. The company later claimed it had not known of OxyContin’s abuse problems until February 2000. Yet the 1995 application reviewed by Food and Drug Administration examiner Curtis Wright described the immediate release that could follow crushing a tablet, withdrawal symptoms observed during trials, and the amount of oxycodone recoverable from a crushed pill. Those details were part of the broader record that concerned families and advocates; they did not, by themselves, establish the allegations in White’s employment suit.

The Trial and Verdict

In 2005, Ed Bisch drove twelve hours from Philadelphia to sit beside Lee Nuss in a Tampa federal courtroom. White’s case was the first against Purdue to progress beyond summary judgment. She sought $138,000 for lost wages and $690,000 for emotional pain. Since her dismissal, she had been depressed and anxious; she had never previously been fired from a job. Bisch’s presence made the courtroom a place where the families’ campaign and the former representative’s personal claim met, though the claim remained White’s to prove.

The imbalance was conspicuous to the people supporting her. Purdue had ten lawyers on its side, apart from staff, and was represented by the Atlanta firm King and Spalding. White had one attorney. Her lawyer estimated that Purdue spent $500,000 defending the case, a figure the company declined to confirm. Bisch later recalled that the families believed Purdue expected them to lose momentum. For supporters, the scale of the defense reinforced the sense that they were confronting not only a disputed account of a firing but also a corporation with considerable resources.

The jury found for Purdue. The company’s lawyer characterized the dispute as a personal disagreement about promoting the drug legally. White believed that calling on pill prescribers who were acting illegally was itself unlawful, but her lawyer did not prove that Purdue’s sales strategies were illegal. The verdict thus resolved the claim before the jury without establishing that White’s account of her firing was true or that the broader concerns about OxyContin had been answered.

What the Case Could and Could Not Prove

A central constraint was the difference between evidence that troubled advocates and evidence admissible and sufficient in this particular case. At Purdue’s request, the government’s highly critical 2003 Government Accountability Office study of its marketing practices was excluded from the trial. The jury was left to decide White’s claim on the evidence it could consider, rather than on the full public controversy surrounding the company’s marketing. The distinction was consequential: information that might support public criticism did not automatically prove the specific legal allegation before the court.

The outcome reflected a wider difficulty in bringing civil cases against Purdue. During the first decade of OxyContin’s existence, the legal system had not proved that the drug’s makers had broken the law. Purdue publicized victories in other civil suits and portrayed the dismissals as grounds for defending future cases vigorously. At the same time, it faced hundreds of pending lawsuits and substantial legal expenses. White’s defeat therefore did not end the larger dispute; it showed how a court could reject a claim even as questions about marketing, prescribing, and harm continued to accumulate outside the courtroom.

The Wider Stakes

The lawsuit’s limits sit within a book that traces different institutional responses to opioid use. Earlier in Roanoke, heroin had largely been treated as an inner-city drug associated with a small, mostly Black population, and was often described as invisible and isolated. Later, as predominantly white opioid users came to public attention, officials and advocates increasingly argued that arrest alone could not resolve the crisis. Yet the book also notes that Black and Hispanic people remained disproportionately represented among drug offenders, while doctors prescribed painkillers to people of color at lower rates than to white patients, in part because of distrust and assumptions about misuse.

That contrast matters to the lawsuit’s place in the larger account. White’s claim was an effort to test corporate responsibility through civil law, while other people caught in the drug economy encountered criminal prosecution, imprisonment, or barriers to treatment. The book describes an alternative approach associated with Bryan Stevenson and the Equal Justice Initiative: diverting some low-level offenders toward housing, case management, employment services, and harm reduction. The juxtaposition does not make White’s case a direct cause of those later proposals. Instead, it places the suit within a broader question about which institutions are held accountable, and which people are offered treatment rather than punishment.

For RAPP’s supporters, the verdict brought disappointment rather than resolution. Lee Nuss told Bisch that they had believed they were doing something, only to feel that nobody would act. Yet the case preserved a specific challenge to Purdue’s account: a former representative said she had been dismissed for refusing to sell to doctors who overprescribed OxyContin. The jury did not find that challenge proved. Its importance lies in the gap it made visible between a family’s conviction, an employee’s allegation, the public evidence surrounding the drug, and the narrower question a civil court could decide.